Presentation is loading. Please wait.

Presentation is loading. Please wait.

Thomas A. d‘Amato, MD, PhD, Rodney J

Published byAndrew Morris Chambers Modified over 6 years ago

Similar presentations

Presentation on theme: "Thomas A. d‘Amato, MD, PhD, Rodney J"— Presentation transcript:

1 Chemotherapy resistance and oncogene expression in non–small cell lung cancer 
Thomas A. d‘Amato, MD, PhD, Rodney J. Landreneau, MD, William Ricketts, PhD, Weidong Huang, MD, PhD, Ricardo Parker, PhD, Eugene Mechetner, MD, Ing-Ru Yu, MS, James D. Luketich, MD  The Journal of Thoracic and Cardiovascular Surgery  Volume 133, Issue 2, Pages (February 2007) DOI: /j.jtcvs Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

2 Figure 1 The frequency of chemotherapy resistance for NSCLC tumor cultures exposed to cisplatin (CPLAT), carboplatin (CARBP), etoposide (VP16), paclitaxel (TAXOL), vinorelbine (NAVBL), docetaxel (TAXTR), and gemcitabine (GEMCB) are shown as percentages. Low drug resistance (LDR) is inhibition of growth 1 SD above the population median; intermediate drug resistance (IDR) is inhibition between the population median and 1 SD below the median; and extreme drug resistant (EDR) tumors are 1 SD below the median population. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

3 Figure 2 Correlation and concurrent chemotherapy resistance illustrating congruent patterns for NSCLC tumor cultures exposed in separate assays to like agents, cisplatin (CPLAT) and carboplatin (CARBO) (N = 1099, R = 0.76) (A) or to vinblastine (VIN) and vincristine (VCR) (N = 28, R = 0.92) (B), are shown as percent colony inhibition (PCI) for each drug tested. Each data point (jittered for clarity) represents the combined in vitro response for a single tumor culture. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

4 Figure 3 Concurrent chemotherapy resistance patterns for NSCLC tumor cultures exposed in separate assays to one of four standard platinum-based chemotherapy doublets. A, Carboplatin (CARBO) and paclitaxel (TAXOL) (N = 1523, R = 0.189); B, cisplatin (CPLAT) and navelbine (NAVBL) (N = 1314, R = 0.018); C, cisplatin (CPLAT) and gemcitabine (GMCB) (N = 741, R = 0.182); and D, cisplatin (CPLAT) and docetaxel (TAXOT) (N = 994, R = 0.09) are shown for each pair as percent colony inhibition (PCI) for each drug tested. Each data point (jittered for clarity) represents the combined in vitro response for a single tumor culture. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

5 Figure 4 Kaplan–Meier estimates of overall survival (A) and the time to progression of disease (B) in the ECOG study patients enrolled according to their assigned treatment (From Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non–small-cell lung cancer. N Engl J Med. 2002;346:92-8. Reprinted by permission of the Massachusetts Medical Society. Copyright 2002 Massachusetts Medical Society. All rights reserved). The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /j.jtcvs ) Copyright © 2007 The American Association for Thoracic Surgery Terms and Conditions

Download ppt "Thomas A. d‘Amato, MD, PhD, Rodney J"

Similar presentations

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT)  Neal E. Dunlap,
Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience  Debra P. Ritzwoller, PhD, Nikki.

Comparative Effectiveness of Adjunctive Bevacizumab for Advanced Lung Cancer: The Cancer Research Network Experience  Debra P. Ritzwoller, PhD, Nikki.
Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer  Robert Klein, MS, Catherine.

Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer  Robert Klein, MS, Catherine.
Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L

Michael Y. Chang, MD, MPH, Steven J. Mentzer, MD, Yolonda L
Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.

Characteristics and outcomes of secondary nodules identified on initial computed tomography scan for patients undergoing resection for primary non–small.
Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data  Chris R. Kelsey, MD, Kristin.

Local recurrence after surgery for non–small cell lung cancer: A recursive partitioning analysis of multi-institutional data  Chris R. Kelsey, MD, Kristin.
Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,

Effect of tumor size on prognosis in patients with non–small cell lung cancer: The role of segmentectomy as a type of lesser resection  Morihito Okada,
Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 

Prognostic significance of histologic differentiation, carcinoembryonic antigen value, and lymphovascular invasion in stage I non–small cell lung cancer 
Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.

Impact of tumor size on outcomes after anatomic lung resection for stage 1A non–small cell lung cancer based on the current staging system  Shamus R.
Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients 

Which patients should be operated on after induction chemotherapy for N2 non–small cell lung cancer? Analysis of a 7-year experience in 175 patients 
Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.

Randomized Phase II Trial of Cisplatin, Etoposide, and Radiation Followed by Gemcitabine Alone or by Combined Gemcitabine and Docetaxel in Stage III A/B.
Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.

Outcomes of unexpected pathologic N1 and N2 disease after video-assisted thoracic surgery lobectomy for clinical stage I non–small cell lung cancer  Hong.
Ground glass opacity of the lung: The veil that needs lifting

Ground glass opacity of the lung: The veil that needs lifting
Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis  Whitney S. Brandt, MD, Wanpu.

Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis  Whitney S. Brandt, MD, Wanpu.
Centers for Disease Control “increased-risk” organ donor: Not so risky?  Francis D. Pagani, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery 

Centers for Disease Control “increased-risk” organ donor: Not so risky?  Francis D. Pagani, MD, PhD  The Journal of Thoracic and Cardiovascular Surgery 
A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.

A Pharmacogenomic Study of Docetaxel and Gemcitabine for the Initial Treatment of Advanced Non-Small Cell Lung Cancer  W Jeffrey Petty, MD, Sommer N.
John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N

John M. Varlotto, MD, Abram Recht, MD, John C. Flickinger, MD, Laura N
William M. DeCampli, MD, PhD 

William M. DeCampli, MD, PhD 
Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430  Thomas E.
Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial  Stacey.

Patterns of survival and recurrence after surgical treatment of early stage non–small cell lung carcinoma in the ACOSOG Z0030 (ALLIANCE) trial  Stacey.

Similar presentations

Ads by Google